TransTech Pharma

About:

TransTech Pharma is engaged in the discovery, development, and commercialization of human therapeutics.

Top Investors: Novo Nordisk, National Institutes of Health, MacAndrews & Forbes, Incorporated, Cephalon, Forest Laboratories

Description:

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Total Funding Amount:

$75.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

High Point, North Carolina, United States

Founded Date:

1999-01-01

Founders:

Adnan Mjalli

Number of Employees:

51-100

Last Funding Date:

2010-06-08

IPO Status:

Private

Industries: